Abstract
It has been proven that inactivated COVID-19 vaccines are safe and effective in general population with intact immunity. However, their safety and immunogenicity have not been demonstrated in people living with HIV (PLWH). In this study, we compared the immunogenicity of an inactivated COVID-19 vaccine between healthy individuals (n=28) and HIV-1 infected participants stable on combined antiretroviral treatment (cART) (n=42). All the HIV-1 infected participants had a CD4+ T cell count of above 200 cells/μL both at baseline and 4 weeks after vaccination. Comparable RBD binding antibody and neutralizing antibody responses were elicited in PLWH and healthy individuals after two-dose vaccination. Further analyses showed that PLWH with low baseline CD4+/CD8+ T cell ratios (<0.6) responded poorly to the vaccination compared with PLWH with medium (0.6∼1.0) or high (≥1.0) baseline CD4+/CD8+ T cell ratios (P<0.01). No solicited adverse reaction was observed in both cohorts. The CD3+, CD4+ and CD8+ T cell counts of PLWH decreased significantly after vaccination, but it did not lead to any adverse clinical manifestation. On the contrary, we found that the general burden of HIV-1 among PLWH decreased significantly (P=0.0059) after two doses of vaccination. Collectively, our data demonstrate that the inactivated COVID-19 vaccine is safe and immunogenic in PLWH who are stable on cART with unsuppressed CD4 counts.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was funded by the National Natural Science Foundation of China (Grant No. 81971559, 82041010).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was approved by the Research Ethics Committee of Hubei CDC (approval reference number: HBCDC-AF/SC-08/02.0)
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data that support the findings of this study are available from the corresponding author upon reasonable request.